Ornidazole

Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease[1][2][3].

Product Specifications

CAS Number

[16773-42-5]

Product Name Alternative

Ro 7-0207

UNSPSC

12352005

Hazard Statement

H302

Target

Antibiotic; Bacterial; Hedgehog; Parasite

Type

Natural Products

Related Pathways

Anti-infection; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/ornidazole.html

Purity

99.97

Solubility

DMSO : ≥ 100 mg/mL|H2O : 10 mg/mL (ultrasonic)

Smiles

CC1=NC=C([N+]([O-])=O)N1CC(CCl)O

Molecular Formula

C7H10ClN3O3

Molecular Weight

219.63

Precautions

H302

References & Citations

[1]Rutgeerts, P., et al., Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology, 2005. 128 (4) : p. 856-61.|[2]Goldstein, E.J., V.L. Sutter, and S.M. Finegold, Comparative susceptibilities of anaerobic bacteria to metronidazole, ornidazole, and SC-28538. Antimicrob Agents Chemother, 1978. 14 (4) : p. 609-13.|[3]Evyapan G, et al., Ornidazole suppresses CD133+ melanoma stem cells via inhibiting hedgehog signaling pathway and inducing multiple death pathways in a mouse model. Croat Med J. 2022 Oct 31;63 (5) :461-474.